Patents by Inventor Soo Yong Chung
Soo Yong Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981659Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: GrantFiled: March 17, 2022Date of Patent: May 14, 2024Assignee: Yuhan CorporationInventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
-
Publication number: 20230021395Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: ApplicationFiled: March 17, 2022Publication date: January 26, 2023Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
-
Publication number: 20220409598Abstract: Methods of treating a subject with diabetes or pre-diabetes include administering an effective amount of a phenyl propionic acid of the Formula (I), an isomer, or a pharmaceutically acceptable salt thereof to the subject to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level.Type: ApplicationFiled: June 17, 2022Publication date: December 29, 2022Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Jong Min YOON, Don-Gil Lee, In-Gyu Je, YoonSung Song, JunGu Park, Soo Yong Chung, Jung Ho Kim, Yearin Jun
-
Patent number: 11453656Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: GrantFiled: April 18, 2018Date of Patent: September 27, 2022Assignee: Yuhan CorporationInventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
-
Patent number: 11046742Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: GrantFiled: April 19, 2017Date of Patent: June 29, 2021Assignee: YUHAN CORPORATIONInventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Publication number: 20210139461Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: ApplicationFiled: April 18, 2018Publication date: May 13, 2021Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
-
Publication number: 20190153055Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: ApplicationFiled: April 19, 2017Publication date: May 23, 2019Inventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Patent number: 8288386Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: GrantFiled: November 10, 2009Date of Patent: October 16, 2012Assignee: LG Life Sciences Ltd.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Patent number: 8236955Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: GrantFiled: June 13, 2011Date of Patent: August 7, 2012Assignee: LG Life Sciences Ltd.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Patent number: 8183243Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: GrantFiled: June 13, 2011Date of Patent: May 22, 2012Assignee: LG Life Sciences Ltd.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Patent number: 8039622Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: GrantFiled: November 10, 2009Date of Patent: October 18, 2011Assignee: LG Life Sciences Ltd.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, Dong Sup Shim, Soo Yong Chung
-
Publication number: 20110245500Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: ApplicationFiled: June 13, 2011Publication date: October 6, 2011Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Publication number: 20110237795Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: ApplicationFiled: June 13, 2011Publication date: September 29, 2011Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Publication number: 20110224219Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: ApplicationFiled: November 10, 2009Publication date: September 15, 2011Applicant: LG LIFE SCIENCES LTD.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Patent number: 7879852Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.Type: GrantFiled: July 13, 2007Date of Patent: February 1, 2011Assignee: LG Life Sciences Ltd.Inventors: Sung Pil Choi, In Ae Ahn, Sang Hyup Lee, Sang Dae Lee, Mi Sook Shin, Koo Lee, Deog Young Choi, Dong Sup Shim, Hyeon Joo Yim, Min Kyung Yoon, Soo Yong Chung, Jung Ae Lee, Yong Hwa Ha, Young Kwan Kim, Oeuk Park, Hyun Min Lee, Youn Hoa Kim
-
Publication number: 20100120783Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.Type: ApplicationFiled: November 10, 2009Publication date: May 13, 2010Applicant: LG LIFE SCIENCE LTD.Inventors: Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
-
Publication number: 20090298829Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.Type: ApplicationFiled: July 13, 2007Publication date: December 3, 2009Inventors: Sung Pil Choi, In Ae Ahn, Sang Hyup Lee, Sang Dae Lee, Mi Sook Shin, Koo Lee, Deog Young Choi, Dong Sup Shim, Hyeon Joo Yim, Min Kyung Yoon, Soo Yong Chung, Jung Ae Lee, Yong Hwa Ha, Young Kwan Kim, Oeuk Park, Hyun Min Lee, Youn Hoa Kim